Engineered Immune Effectors Against Ovarian Cancer

Recruiting Phase 1 Phase 2 Interventional Study
Ovarian Cancer
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
10 – 80
Sex
Female
Trial phase
Phase 1/2
Study type
Interventional
Purpose
Treatment
Participants needed
20 (estimated)
Sponsor
Shenzhen Geno-Immune Medical Institute · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

This is a single-arm, open-label, phase I/II trial to evaluate the safety and efficacy of ovarian cancer specific cytotoxic lymphocytes (OC-CTLs) in women.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. Written, informed consent obtained prior to any study-specific procedures. 2. Age older than 10 years. 3. Eastern Cooperative Oncology Group (ECOG) PS of 0 or 1. 4. Expected survival ≥ 12 weeks. 5. Histologically confirmed and documented high risk International Federation of …
Contacts

Lung-Ji Chang, PhD

+86 0755-86573763

c@szgimi.org

CONTACT